TickerFacts.

Jyong Biotech Ltd. (MENS): Shareholders' Equity

Annual figures by period end, from SEC filings.

-$24.91M
As of 2025-12-31
2023-12-31: -$34.07M2024-12-31: -$36.52M2025-12-31: -$24.91M-$24.91M
2023-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31-$24.91Mn/m2026-05-15, Balance as of period end
2024-12-31-$36.52Mn/m2026-05-15, Balance as of period end
2023-12-31-$34.07Mn/a2026-05-15, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Jyong Biotech Ltd. (MENS)2025-12-31-$24.91Mn/m
Abvc Biopharma, Inc. (ABVC)2025-12-31$11.11M+806.2%
Annovis Bio, Inc. (ANVS)2025-12-31$16.85M+81.0%
Nexentis Technologies Inc. (NXTS)2025-12-31$16.01M+237.1%
Quoin Pharmaceuticals Ltd. (QNRX)2025-12-31$13.12M+42.5%
Evofem Biosciences, Inc. (EVFM)2025-12-31-$74.34Mn/m
Emmaus Life Sciences, Inc. (EMMA)2025-12-31-$63.61Mn/m
Phio Pharmaceuticals Corp. (PHIO)2025-12-31$20.15M+326.6%
BriaCell Therapeutics Corp. (BCTX)2025-07-31$17.33Mn/m

Compare MENS, ABVC, ANVS, NXTS side by side · Screen every company in Pharmaceutical Preparations ↗